Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism
Phase 1
Completed
- Conditions
- HIV Infections
- Registration Number
- NCT00135434
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
This study examined the effects of two commonly prescribed HIV drugs on the way the body metabolizes glucose, insulin and fat.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
- Healthy volunteers
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Insulin sensitivity by euglycemic hyperinsulinemic clamp method
- Secondary Outcome Measures
Name Time Method Lipids and lipoproteins Insulin sensitivity by oral glucose tolerance
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link HIV protease inhibitors to glucose and insulin metabolism disruption?
How do HIV protease inhibitors compare to standard-of-care antiretrovirals in inducing insulin resistance?
Which biomarkers correlate with metabolic changes in HIV patients treated with protease inhibitors?
What adverse metabolic effects are associated with Bristol-Myers Squibb's HIV protease inhibitor trials?
How do combination therapies with HIV protease inhibitors and metabolic regulators impact lipid profiles?
Trial Locations
- Locations (1)
Clinical Pharmacology Unit, Bristol-Myers Squibb Company
🇺🇸Hamilton, New Jersey, United States